Aviado · Research
Longevity Daily
Thursday, November 19, 2026
Listen
Today's Brief
Alzheimer's research dominates today: a tau-targeting drug called diranersen cut cognitive decline by roughly half in a major trial — the most significant Alzheimer's result in years. GLP-1 drugs get scrutinized on two fronts: a Science review suggests they may protect the aging brain, while a BMJ study finds most users are dangerously low on key nutrients. If you take turmeric for joint pain, a comprehensive Cochrane analysis delivers bad news — no meaningful benefit over placebo. Also today: the FDA moves to formally legalize NAC as a dietary supplement, ending years of regulatory limbo.
10 stories3 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Alzheimer's Drug Diranersen Halves Cognitive Decline in Landmark Trial
Patients given low-dose diranersen injections showed roughly 54% less decline on memory and thinking tests over nearly two years, according to data from a major trial backed by Biogen — described by researchers as 'very encouraging.' The drug works by lowering tau protein, the tangled fibers that choke neurons in Alzheimer's disease, and received FDA Fast Track designation in 2025, putting it on the fastest possible path to approval. For the tens of millions at risk of Alzheimer's, this is the most dramatic tau-targeting result to date, though a Phase 3 trial is still needed to confirm efficacy before the drug reaches patients. Early-stage Alzheimer's patients and their families should watch this one closely.
Read more →Citicoline: The Brain Supplement With Two Distinct, Measurable Mechanisms
Unlike most nootropics that deliver marginal results, citicoline works through two independently verified pathways: it rebuilds damaged neuronal membranes while simultaneously increasing dopamine receptor density — which explains why users actually feel a difference. Human trials show real-world improvements in memory, attention, and processing speed, with the most striking data from Parkinson's patients who reduced prescription medication needs by up to 50% while maintaining symptom control. For daily brain optimization, 500–1,000 mg is the evidence-backed dose range, with benefits typically appearing within four to twelve weeks of consistent use.
Read the full Aviado analysis →Tracking 219,000 People: Younger Generations Are Cognitively Aging Better Than Their Parents
A large study following over 219,000 people found that younger generations are reaching old age with sharper memories and losing cognitive function more slowly than prior generations — a rare optimistic data point in the dementia space. Researchers credit decades of improvements in education, cardiovascular disease management, and reduced smoking as the likely drivers. The finding reinforces that modifiable lifestyle choices made earlier in life compound meaningfully over decades, and that dementia is not simply an inevitable part of aging.
Read more →Supplements & Compounds
Cochrane Review: Turmeric Supplements Show No Meaningful Benefit for Knee Osteoarthritis
A comprehensive Cochrane-backed review of clinical trials found that turmeric supplements had no meaningful effect on quality of life for people with knee osteoarthritis, performing no better than placebo or existing anti-inflammatory drugs. The trials reviewed ranged from four weeks to three months — short, but long enough to detect meaningful effects if they existed. If you're taking curcumin specifically for joint pain relief, the evidence now squarely points elsewhere; consider speaking with your doctor about interventions with a stronger evidence base.
Read more →GLP-1 Users Are Running Low on Fiber, Vitamin D, and Iron — Here's What to Do
A study published in BMJ Nutrition found that more than three-quarters of people on GLP-1 drugs like Wegovy weren't getting enough fiber or vitamin D from their diets, with half also falling short on iron — a natural consequence of dramatically reduced caloric intake. These deficiencies can quietly undermine the metabolic and longevity benefits the drugs are meant to deliver. If you or someone you know is on a GLP-1 medication, targeted supplementation and regular nutrient monitoring should be an explicit part of the treatment plan.
Read more →Research & Papers
'Light and Sound' Alzheimer's Therapy Fails Its Long-Awaited Clinical Trial
A device using flickering light and rhythmic clicking sounds to stimulate gamma brain waves failed to slow memory loss in Alzheimer's patients in a highly anticipated clinical trial, according to results reported by Nature. The approach, developed by MIT researchers, generated widespread buzz following promising animal and early-stage human data. This is a pointed reminder that compelling mechanisms in mice — and even small pilot studies — frequently don't survive rigorous large-scale testing, a pattern worth bearing in mind as the next wave of neurotech devices moves into trials.
Read more →GLP-1 Weight-Loss Drugs May Protect the Aging Brain — But Timing Is Everything
A review published in Science examines how GLP-1 receptor agonists may shield the brain from cognitive decline through direct neurological mechanisms and improved cardiometabolic health, with observational data showing lower dementia risk among type 2 diabetes patients on these drugs. However, clinical trials have so far failed to demonstrate convincing benefits in people who already have established Alzheimer's disease. The emerging picture is that GLP-1 drugs may be more valuable as cognitive prevention tools than as treatments — a meaningful distinction for anyone weighing their long-term use.
Read more →Lifestyle & Nutrition
Scientists Find a Distinctive Pattern in the Gut Microbiomes of Centenarians
Researchers studying gut microbiomes of centenarians identified specific microbial changes consistently associated with exceptional longevity, potentially pointing to new targets for healthy aging interventions. The scientists caution that these are associations — it doesn't prove the microbes cause long life, and engineered bacteria approaches remain experimental and far from clinical use. Even so, the findings add meaningful weight to the growing consensus that the gut-longevity axis is real and that microbiome health is a lever worth optimizing.
Read more →Industry & Policy
FDA Proposes Legalizing NAC as a Dietary Supplement, Ending Years of Regulatory Limbo
The FDA has proposed reversing its exclusion of N-acetyl-L-cysteine (NAC) from the definition of a dietary supplement — a first-of-its-kind regulatory move that would formally legitimize a compound widely sold and used for liver support, respiratory health, and antioxidant effects. The proposed rule preserves safety oversight and claim restrictions while ending the legal ambiguity that has shadowed NAC products since the FDA first flagged its drug-prior-approval status. For supplement brands and the millions of consumers already using NAC, this is a significant regulatory green light.
Read more →Hone Health Raises $228M as Institutional Capital Floods Into Longevity Platforms
New York-based Hone Health secured $228 million — $28M in Series A equity led by Jay-Z's MarcyPen and $200M in growth financing from General Catalyst's Customer Value Fund — to scale its physician-led longevity care platform well beyond its testosterone clinic origins. The capital will fund its proprietary 'Longevity OS' clinical AI, peptide therapy programs, and clinical trial infrastructure for both men and women. Hone's raise reflects a broader institutional conviction that subscription-based longevity care is becoming a durable, mainstream healthcare category.
Read more →